- Global Pharma News & Resources

The global biologics market is estimated to reach $250bn in 2023

The global biologics market is estimated to reach $250bn in 2023

PR Newswire

NEW YORK, Dec. 24, 2018

NEW YORK, Dec. 24, 2018 /PRNewswire/ --

Protein Therapeutics, Monoclonal Antibodies, Fusion Proteins, Regenerative Medicines, Insulin, Other Recombinant Hormones, Plasma & Recombinant Coagulating Factors, Interferons, Enzyme Replacement, Stem Cell Therapies, Tissue Engineered Products, Gene Therapies

Read the full report:

The global biologics market is estimated to reach $250bn in 2023. The market is expected to grow at a CAGR of 4.8% from 2018 to 2023. In 2017, the monoclonal antibodies submarket held 36.3% share of the global biologics market.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 303-page report you will receive 166 charts– all unavailable elsewhere.
The 303-page report provides clear detailed insight into the global biologics market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope
- Global Biologics Market outlook from 2018-2028

Global Biologics Submarkets analysis and forecast from 2018-2028:
- Protein therapeutics, with sub-forecasting for insulin, other recombinant hormones, plasma and recombinant coagulating factors, interferons, enzyme replacement and other agents
- Monoclonal antibodies (mAbs)
- Fusion proteins
- Regenerative medicine, with sub-forecasting for stem cell treatment, tissue engineering and gene therapy
- Vaccines

Analysis and forecast from 2018-2028 for selected leading biologics in the market:
- Lantus
- NovoLog/NovoRapid
- Humalog
- Avonex
- Rebif
- Humira
- Remicade
- Tysabri
- Herceptin
- Kadcyla
- Perjeta
- Enbrel
- Eylea
- OsteoCel Plus
- Trinity Evolution and Trinity Elite
- Apligraf
- Dermagraft

This report provides individual revenue forecasts from 2018-2028 for these national markets:
- The US
- Japan
- Germany
- France
- UK
- Italy
- Spain
- China
- India
- Russia
- Brazil

Our study discusses the selected leading companies that are the major players in the biologics market:
- AbbVie
- Amgen
- AstraZeneca
- Bayer
- Eli Lilly
- GlaxoSmithKline (GSK)
- Johnson & Johnson
- Merck & Co., Inc.
- Novartis
- Pfizer
- Roche
- Sanofi S.A.

This report discusses factors that drive and restrain this market. As well as opportunities and trends in this market.
This report discusses the SWOT and STEP Analysis of the biologics market.

Read the full report:

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

Contact Clare:
US: (339)-368-6001
Intl: +1 339-368-6001

View original content:

SOURCE Reportlinker

Editor Details

Last Updated: 24-Dec-2018